Investor relations

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
March 5, 2026 10:04 pm ET
Delayed at least 20 minutes

Latest news, events & financials

February 28, 2026

KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)

February 28, 2026

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

February 27, 2026

KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer

View all

March 03, 2026

Webcast

TD Cowen 46th Annual Health Care Conference

Webcast Transcript

February 03, 2026

Earnings

Q4 2025 Earnings Call

Webcast 4Q25 Merck Earnings Presentation 4Q25 Merck Earnings Announcement 4Q25 Merck Other Financial Disclosures 4Q25 Other Financial Disclosures (Excel) 4Q25 Prepared Remarks Transcript

January 12, 2026

Webcast

44th Annual J.P. Morgan Healthcare Conference

Webcast Transcript Presentation

View all

4Q25 Merck Earnings Presentation

4Q25 Merck Other Financial Disclosures

4Q25 Other Financial Disclosures (Excel)

4Q25 Prepared Remarks

Q1 2026 Earnings Call

April 30, 2026

Merck office building and research site in South San Francisco

See full agenda

Our pipeline shows our relentless pursuit of the next breakthrough.

Explore our pipeline

Phase II programs

50+

Phase III programs

30+

Under review

Illustration of leaders speaking on stage

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership

Image showing microbes in a lab dish on the left and earth on the right

Sustainability

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Purpose for Progress Impact Report 2024/2025

Download our Sustainability financing documents:

2023 Sustainability bond allocation report

2022 Sustainability bond allocation report

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories

Innovation

Our Q1 2025 financial results

Merck’s (NYSE: MRK) Q1 2025 results reflect strong progress, including increasing contributions from newer medicines and vaccines. Our company announced Q1 worldwide sales of $15.5 billion. “Our company made strong progress to start the year, with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline,” said Rob Davis, chairman […]

illustration of people on top of hexagon shapes

Innovation

Our Q4 and full-year 2024 financial results

Merck’s (NYSE: MRK) Q4 and full-year 2024 results reflect strong growth. Our company announced Q4 worldwide sales of $15.6 billion, an increase of 7% from Q4 2023. Full-year 2024 worldwide sales were $64.2 billion, an increase of 7% from full-year 2023. “We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including […]

Two people interacting with a bar graph made

Innovation

Our Q3 2024 financial results

Merck’s (NYSE: MRK) Q3 2024 financial results represent strong progress across the business and our diverse pipeline. Our company announced worldwide sales of $16.7 billion, an increase of 4% from Q3 2023. “Our third-quarter results were strong, as we continue to make progress heading into 2025 and beyond,” said Rob Davis, chairman and chief executive officer. […]

Innovation